In patients with treatment-resistant depression, higher levels of IL-17A were found in the blood [3] (Nothdurfter et al., 2021), and pre-treatment level of RORyt mRNA can serve as a biomarker of response to therapy [108]. The gene discussed is IL17A; the disease is depressive symptom measurement.